Variant Manifestation of Cowden Disease in Japan: Hamartomatous Polyposis of the Digestive Tract with Mutation of the PTEN Gene  by Kurose, Keisuke et al.
Am. J. Hum. Genet. 64:308–310, 1999
308
Letters to the Editor
Am. J. Hum. Genet. 64:308, 1999
Variant Manifestation of Cowden Disease in Japan:
Hamartomatous Polyposis of the Digestive Tract with
Mutation of the PTEN Gene
To the Editor:
Because of the clinical heterogeneity and complexity of
the group of disorders collectively known as inherited
hamartoma syndromes, several attempts have beenmade
to classify them into distinct categories. In the May issue
of this Journal, Eng and Ji (1998) reviewed recent pro-
gress in molecular characterization of these syndromes
and classified them into four clinical entities: Cowden
disease (CD [MIM 158350]), Bannayan-Ruvalcaba-Ri-
ley syndrome (BRR [MIM 153480]), Peutz-Jeghers syn-
drome (PJS [MIM 175200]), and juvenile polyposis syn-
drome (JPS [MIM 174900]). Despite some progress in
molecular characterization, specific diagnoses of these
disorders remain difficult because their phenotypic spec-
tra overlap and because the penetrance of symptoms is
age related. Clinical syndromic diagnosis is also depen-
dent on many factors, such as the nature and type of
the first clinical symptoms and the medical discipline of
the individual(s) diagnosing the syndrome.
PTEN, a gene mapping to 10q23, encodes a dual-
specificity phosphatase and is also called MMAC1 or
TEP1 (Li and Sun 1997; Li et al. 1997; Steck et al. 1997).
PTEN has been identified as the susceptibility gene for
CD and BRR (Liaw et al. 1997; Marsh et al. 1997), and
it appears that PTEN mutations are detected more fre-
quently in CD and BRR patients when strict clinical
criteria are applied to the selection of test subjects (Liaw
et al. 1997; Marsh et al. 1997, 1998). LKB1/STK11, a
serine threonine kinase gene at 19p13.3, has been iden-
tified as a susceptibility gene for PJS (Hemminki et al.
1998; Jenne et al. 1998). As for JPS, however, some
controversy exists about its molecular basis. Three pos-
sibilities have been raised: (1) germ-line mutations of the
SMAD4/DPC4 gene at 18q21.1 are known to be re-
sponsible for JPS in some affected families (Howe et al.
1998), (2) PTEN mutations appear to be the predis-
posing elements for some patients diagnosed with JPS
(Lynch et al. 1997; Olschwang et al. 1998); and (3) yet
another putative locus (“JP1”), centromeric to PTEN
on chromosome 10q, has been linked to JPS in some
affected families (Jacoby et al. 1997). The low pene-
trance of CD, the sharing of some phenotypic features
between CD and JPS, and the possible genetic hetero-
geneity of JPS make diagnosis complex and confusing.
Pathognomonic hallmarks of CD patients are facial
trichilemmomas, acral keratoses, and verucoid or pap-
illomatous papules. This triad of skin lesions occurs in
99% of CD patients (Hanssen and Fryns 1995; Longy
and Lacombe 1996). Other, less frequent manifestations
of CD include thyroid adenomas or goiters (occurring
in 40%–60% of CD patients), breast fibroadenomas
(70% of affected females), hamartomatous gastrointes-
tinal polyps (35%–40%), andmacrocephaly (38%) (Eng
1998; Marsh et al. 1998). JPS is characterized by gas-
trointestinal hamartomatous polyps and an increased
risk of gastrointestinal cancer (Olschwang et al. 1998).
We examined a 35-year-old Japanese man who had
been followed clinically for JPS because of numerous
hamartomatous polypoid lesions throughout the entire
digestive tract, from esophagus to rectum. Although he
had none of the pathognomonic skin lesions of CD, we
extended our clinical examination to the patient’s whole
body and tested him for mutation of the PTEN gene, in
view of Eng’s proposal (1998) that PTEN mutation can
be a useful diagnostic marker for incompletely expressed
CD. After informed consent was obtained, genomic
DNAs prepared from blood from the patient and from
members of his family were examined by direct sequenc-
ing of the entire coding region and exon-intron bound-
aries of PTEN, according to procedures we have de-
scribed elsewhere (Kurose et al. 1998). The patient’s
father died of brainstem infarction, a condition unre-
lated to CD. No other members of his family have been
diagnosed as having CD.
The patient was found to be heterozygous for a GrA
transition at the second nucleotide of codon 130, which
would result in a substitution of Gln for Arg (R130Q).
The patient’s mother and sister did not carry this mu-
tation (fig. 1), nor was it detected in 192 chromosomes
from control Japanese individuals. On closer examina-
tion, which included ultrasonography and computed to-
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Figure 1 DNA sequencing of the PTEN gene in the family of a patient with variant CD. The patient (blackened square) carries a GrA
transition in exon 5, which is not present in his unaffected mother and sister. Eu: uninformative evaluation.
mography, we found a small thyroid adenoma, a few
papillomatous papules in his right hand, and a lung tu-
mor, which is now being examined for possible malig-
nancy. Thus, molecular testing of the PTEN gene, as
proposed by Eng (1998) in another case of suspected
JPS, led us to a diagnosis of CD in a “JPS” patient who
manifested atypical symptoms of CD. His germ-line mu-
tation had occurred in the core motif of the phosphatase,
at amino acid residue 122–132, encoded by exon 5.
Most of the reported germ-line missense mutations of
the PTEN gene reported in patients with CD have oc-
curred within this core motif (Marsh et al. 1998). Thus,
in terms of PTEN mutation, our case is typical of a CD
entity, although the phenotype is atypical.
Eng and Ji (1998) pointed out that apparent “JPS”
patients who carry PTEN germ-line mutations (Lynch
et al. 1997; Olschwang et al. 1998) may in fact belong
to a category of CD patients whose phenotypic features
are only partially expressed. Eng and Ji (1998) proposed
that the presence of a germ-line PTEN mutation could
be a good diagnostic sign for CD and BRR. In the future,
these inherited hamartoma syndromes should be clas-
sified by types of gene mutations, such as the PTEN
mutation syndrome.
The results described here signal the possibility that a
large number of hidden clinical variants of CDmay exist
among patients who might have escaped correct clinical
diagnosis and may have been treated for JPS. Our work
underscores the usefulness and importance of molecular
methods for achieving differential diagnoses among pa-
tients with gastrointestinal polyposis, because JPS and
CD predispose to completely different types of cancer.
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